Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06341335 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of AK104/Placebo Plus AK109/Placebo And Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma

Name: A Study of AK104/Placebo Plus AK109/Placebo And Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma — clinical trial record (NCT06341335)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 3

SponsorAkeso

Started2024-06-19

View on ClinicalTrials.gov ↗

Amendment history

2024-06-20

Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1

Trial statusNot Yet Recruiting→Recruiting

Start dateestimated 2024-05→confirmed 2024-06-19

Study sites0→1

2024-03-26

Original filing

Akeso

96 trials monitored

See 1 trial at risk

This randomized, multicenter, double-blind, phase 3 study will evaluate the efficacy and safety of the combination of cadonilimab (AK104) and pulocimab (AK109) and paclitaxel compared with paclitaxel in patients with advanced gastric or gastroesophageal junction adenocarcinoma who failed first-line immunochemotherapy.

Trial Details

NCT Number	NCT06341335
Lead Sponsor	Akeso
Conditions	Gastric and Gastroesophageal Junction Adenocarcinoma
Enrollment	506 participants
Start Date	2024-06-19
Primary Completion	2026-11 (estimated)
Study Completion	2027-07 (estimated)
Updated on ClinicalTrials.gov	2024-06-24